Recent Updates on the Johnson & Johnson Coronavirus Vaccine - COVID-19 Clinical Trial
Current COVID-19 Clinical Trial

Recent Updates on the Johnson & Johnson Coronavirus Vaccine

    Add a header to begin generating the table of contents

    Like other pharmaceutical and biotech companies, Johnson & Johnson initiated efforts to develop a COVID-19 vaccine as soon as the novel coronavirus sequence became available in January 2020.  

    At the end of March, Johnson & Johnson announced that its experimental vaccine could be ready for human testing by September 2020, and for regular use shortly thereafter in early 2021.  

    J&J Uses “Proven” Adenoviral Vector Platform 

    The COVID-19 vaccines currently in development are all unique. Some, like Moderna’s mRNA vaccine, use newer, experimental technologies. Others, like Johnson & Johnson’s adenoviral vectors, have been proven as a tried-and-true approach over time.  

    Adenoviral technology has been tested extensively, but it is only used in one commercial vaccine today: the rabies vaccine used to immunize wild animals. The Janssen division of Johnson & Johnson hopes to create the world’s second adenoviral vaccine with its engineered version of adenovirus 26 (Ad26).  

    Ad26 normally causes common colds, but has been disabled to stop replication. A gene for the surface protein from COVID-19 has been “stitched” into the Ad26 vector. As Paul Stoffels, J&J’s chief scientific officer explains, “We learned from what we did in Zika that with the right [Ad26] vector, we can get very significant immunity. We can do it with one dose, but we’re going to test two doses in the clinic.” 

    Why Isn’t J&J Launching Clinical Trials Now? 

    Moderna, Oxford University, and other vaccine leaders are already in the process of completing Phase 1 and Phase 2 clinical studies, but Johnson & Johnson’s Phase 1 trial of its experimental vaccine won’t occur until the fall.  

    Stoffels explains why J&J believes it’s worth the wait: “With vectors like Ad26, you need to get the seeds [copies of the engineered virus] to do biological manufacturing. That takes time to make sure we select the right clones and that we have a stable selection so we can grow the right ones.” 

    Although J&J’s clinical trials will lag behind others in the crowded pharmaceuticals field, the company can accelerate its timeline from a Phase 1 trial of safety and immune responses to a proof-of-concept study thanks to its pre-established safety data. “We are used to recruiting extremely fast, so we could do 250, 500 people in a day and month later, 3 days after the blood is taken, we should be able to know the results,” Stoffels elaborates. 

    Stoffels and the rest of the J&J team envision using thousands of people in an emergency use application of the experimental vaccine in order to achieve a large Phase 2 study in the real world.  

    Thanks to its landmark new partnership with the Biomedical Advanced Research and Development Authority (BARDA), Johnson & Johnson has committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing. If all goes as planned, J&J will have a vaccine ready for emergency use by early 2021.  


    Share this:

    Your choice regarding cookies on this site

    We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    By continuing to access this website you are giving us consent to collect cookies.

    Want to stay informed?

    With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.